- Stocks
- Pharma & Healthcare
- Bafna Pharmaceuticals
Bafna Pharmaceuticals share price
NSE: BAFNAPHPharma & HealthcareDrug Manufacturers - Specialty & Generic
Bafna Pharmaceuticals at a glance
Bafna Pharmaceuticals (NSE: BAFNAPH) closed at ₹470.55 on 19 Oct 2026, up 1.99% on the day. With a market capitalisation of ₹1,113 Cr, it ranks 1420th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 100.3× trailing earnings, against a return on equity of 0.0% in FY20. Over the past year the share price has risen 195.5%. Its 52-week range is ₹94.77 (16 Mar 2026) to ₹470.55 (19 Oct 2026); the last close is 0.0% above the high. Promoters held 75.00% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,113 CrRank 1420 on NSE
- P/E (trailing)
- 100.3×
- Price to book
- -0.49×FY20
- ROE
- 0.0%FY20
- ROCE
- −3.3%FY20
- Debt to equity
- -0.71FY20
- Net profit margin
- −57.5%FY20
- Book value / share
- −₹17.59FY20
- 52-week high
- ₹470.5519 Oct 2026
- 52-week low
- ₹94.7716 Mar 2026
- 1-year return
- +195.5%
- RSI (14-day)
- 94.2
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.99% | +10.4% | +51.3% | +105.5% | +195.5% |
Bafna Pharmaceuticals financials
| Item | FY15 | FY16 | FY17 | FY18 | FY19 | FY20 |
|---|---|---|---|---|---|---|
| Revenue | ₹98 Cr | ₹85 Cr | ₹65 Cr | ₹47 Cr | ₹43 Cr | ₹42 Cr |
| Operating profit | ₹9 Cr | −₹15 Cr | −₹20 Cr | −₹15 Cr | −₹18 Cr | −₹2 Cr |
| Net profit | ₹6 Cr | −₹15 Cr | −₹19 Cr | −₹17 Cr | −₹18 Cr | −₹24 Cr |
| EPS (₹) | ₹3.00 | −₹9.00 | −₹10.00 | −₹7.00 | −₹11.00 | −₹16.00 |
| Cash from operations | ₹11 Cr | ₹1 Cr | −₹1 Cr | −₹7 Cr | −₹2 Cr | −₹34 Cr |
| Total debt | ₹12 Cr | ₹35 Cr | ₹39 Cr | ₹23 Cr | ₹23 Cr | ₹3 Cr |
| Shareholders' equity | ₹72 Cr | ₹58 Cr | ₹43 Cr | ₹38 Cr | ₹19 Cr | −₹4 Cr |
Bafna Pharmaceuticals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| Foreign institutions | 8.53% | 9.34% | 9.34% | 9.34% | 9.34% | 9.34% |
| Non-institutions | 16.47% | 15.66% | 15.66% | 15.66% | 15.66% | 15.66% |
Bafna Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to Bafna Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| GPTHEALTHGPT Healthcare | ₹139.50 | −0.36% | −6.4% | ₹1,145 Cr | 27.1 | — |
| BAJAJHCAREBajaj Healthcare | ₹339.90 | −2.05% | −27.4% | ₹1,144 Cr | 50.4 | — |
| BAFNAPHBafna Pharmaceuticals | ₹470.55 | +1.99% | +195.5% | ₹1,113 Cr | 100.3 | — |
| LINCOLNLincoln Pharmaceuticals | ₹533.40 | −2.58% | +0.9% | ₹1,068 Cr | 12.2 | — |
| SIGACHISigachi Industries | ₹26.70 | −4.13% | −32.9% | ₹1,020 Cr | — | — |
| LAXMIDENTLLaxmi Dental | ₹182.10 | −1.57% | −42.7% | ₹1,001 Cr | 34.6 | — |
| THEMISMEDThemis Medicare | ₹100.30 | −5.47% | −23.6% | ₹924 Cr | — | — |
Ask anything about Bafna Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against BAFNAPH's own history. Try: “Why has BAFNAPH moved over the last three months?” · “Backtest a 50-day moving-average crossover on BAFNAPH over five years” · “Compare BAFNAPH with GPTHEALTH on margins and valuation”
Frequently asked questions about Bafna Pharmaceuticals
What is the share price of Bafna Pharmaceuticals today?
Bafna Pharmaceuticals (NSE: BAFNAPH) last closed at ₹470.55 on 19 Oct 2026. Its 52-week high is ₹470.55 and its 52-week low is ₹94.77.
What is the market cap of Bafna Pharmaceuticals?
Bafna Pharmaceuticals' market capitalisation is ₹1,113 Cr (₹1,113 Cr) at the 19 Oct 2026 close, ranking 1420th among the NSE companies Pivot tracks.
What is the P/E ratio of Bafna Pharmaceuticals?
Bafna Pharmaceuticals trades at a trailing P/E of 100.3. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 34.6.
What is the ROE and ROCE of Bafna Pharmaceuticals?
Return on equity was 0.0% in FY20 and return on capital employed was −3.3% in FY20 (consolidated figures).
Is Bafna Pharmaceuticals a debt-free company?
Bafna Pharmaceuticals is close to debt-free: its debt-to-equity ratio was -0.71 in FY20.
How has Bafna Pharmaceuticals stock performed over the last year?
Bafna Pharmaceuticals' share price has risen 195.5% over the past year, +105.5% over three months and +51.3% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Bafna Pharmaceuticals?
As of 30 Jun 2026: promoters 75.00%, foreign institutions 9.34%, non-institutions 15.66%.
Who are Bafna Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to Bafna Pharmaceuticals by market cap are GPT Healthcare, Bajaj Healthcare, Lincoln Pharmaceuticals, Sigachi Industries, Laxmi Dental and Themis Medicare.
Is Bafna Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Bafna Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on BAFNAPH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with B · all NSE stocks · this page as text